At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 49 enrolled
Drug / intervention
Niclosamide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2/3 Randomized and Placebo-Controlled Study of ANA001 in Moderate and Severe COVID-19 Patients
In Brief
A Phase 3 clinical trial evaluating Niclosamide and Placebo for COVID-19. Completed, enrolled 49 participants across 8 sites.
Detailed Summary
Study of ANA001 in Moderate and Severe COVID-19 Patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartOct 2020
First PostedOct 2020
Primary CompletionFeb 2022
TodayJul 2026
First PostedOct 27, 2020
Enrollment StartOct 7, 2020
Primary CompletionFeb 16, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.7 years ago
Interventions
Niclosamidedrug
Niclosamide is an antihelmintic with in-vitro antiviral activity
Placebodrug
Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients